Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430502 | 0.96 | DYRK1A (0.46) | DYRK1AMAOAMAOBCYP2A6POLB | |
| SCHEMBL568118 | 0.88 | AHR (0.41) | DYRK1ACYP2A6AHRNOTUMMAPT | |
| SCHEMBL9822419 | 0.80 | DYRK1A (0.41) | DYRK1APOLBBRD4AHRMAPT | |
| SCHEMBL5537592 | 0.78 | MAOA (0.50) | DYRK1AMAOAMAOBCYP2A6BRD4 | |
| SCHEMBL20589092 | 0.77 | AHR (0.47) | MAOAMAOBCYP1A2AHRMAPT | |
| SCHEMBL5238902 | 0.76 | MAOA (0.48) | DYRK1AMAOAMAOBCYP2A6PRKCI | |
| SCHEMBL2564157 | 0.76 | MAPT (0.52) | DYRK1AMAOAMAOBCYP2A6BRD4 | |
| SCHEMBL19899072 | 0.76 | MAOA (0.48) | DYRK1AMAOAMAOBCYP2A6BRD4 | |
| SCHEMBL1337967 | 0.76 | CYP2A6 (0.48) | MAOAMAOBCYP2A6BRD4FGFR1 | |
| SCHEMBL14632127 | 0.76 | MAOA (0.48) | DYRK1AMAOAMAOBCYP2A6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-117466723-A | Preparation method of halogenated tetralone | 上海泰坦科技股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-3883932-B1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-03-29 | — | — | EP | disclosed |
| CN-113968855-A | Compound for treating thrombotic diseases | 中国科学院上海药物研究所 | 2022-01-25 | — | — | CN | disclosed |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | NEW YORK UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-5646173-A | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0606661-B1 | Octahydrophenanthrene derivatives and their use as NMDA-Antagonists | HOFFMANN LA ROCHE (CH) | 1997-03-12 | — | — | EP | disclosed |
| CN-1105989-A | Tricyclic 1-aminoethylpyrrol derivative | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | CN | disclosed |
| EP-0657426-A2 | Tricyclic pyrrole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-14 | — | — | EP | disclosed |
| US-5385947-A | For prevention of nerve damage due to reduction of blood or oxygen supplies | HOFFMANN-LA ROCHE INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0606661-A1 | Octahydrophenanthrene derivatives and their use as NMDA-Antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1994-07-20 | — | — | EP | disclosed |
| EP-0591582-A1 | Hexahydrobenzo (f) quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5250539-A | 5-alpha reductase inhibitors; administer as therapy for benign prostatic hyperplasia, hirsutism and acne | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0531026-A1 | Hexahydrobenzo[f]quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-10 | — | — | EP | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | DYRK1A 3858/4885MAOA 4212/4885MAOB 4015/4885 |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | GLI1, GLI2, SHH | DYRK1A 3858/4885MAOA 4212/4885MAOB 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.